Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

348 ARTÍCULOS , VIENDO DEL 226 AL 240

Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease

Allen GI, Amoroso N, Anghel C, Balagurusamy V, Bare CJ, Beaton D, Bellotti R, Bennett DA, Boehme KL, Boutros PC, Caberlotto L, Caloian C, Campbell F, Chaibub Neto E, Chang YC, Chen B, Chen CY, Chien TY, Clark T, Das S, Davatzikos C, Deng J, Dillenberger D, Dobson RJ, Dong Q, Doshi J, Duma D, Errico R, Erus G, Everett E, Fardo DW, Friend SH, Fröhlich H, Gan J, St George-Hyslop P, Ghosh SS, Glaab E, Green RC, Guan Y, Hong MY, Huang C, Hwang J, Ibrahim J, Inglese P, Iyappan A, Jiang Q, Katsumata Y, Kauwe JS, Klein A, Kong D, Krause R, Lalonde E, Lauria M, Lee E, Lin X, Liu Z, Livingstone J, Logsdon BA, Lovestone S, Ma TW, Malhotra A, Mangravite LM, Maxwell TJ, Merrill E, Nagorski J, Namasivayam A, Narayan M, Naz M, Newhouse SJ, Norman TC, Nurtdinov RN, Oyang YJ, Pawitan Y, Peng S, Peters MA, Piccolo SR, Praveen P, Priami C, Sabelnykova VY, Senger P, Shen X, Simmons A, Sotiras A, Stolovitzky G, Tangaro S, Tateo A, Tung YA, Tustison NJ, Varol E, Vradenburg G, Weiner MW, Xiao G, Xie L, Xie Y, Xu J, Yang H, Zhan X, Zhou Y, Zhu F, Zhu H, et al.

Alzheimers Dement. 2016 Jun;12(6):645-53. doi: 10.1016/j.jalz.2016.02.006. Epub 2016 Apr 11.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab

Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C.

J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.

The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis

Szalárdy L, Zádori D, Klivényi P, Vécsei L.

J Alzheimers Dis. 2016 May 7;53(2):373-92. doi: 10.3233/JAD-160037.

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators.

Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.

Exploratory human PET study of the effectiveness of (11)C-ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes in Alzheimer's disease

Ohnishi A, Senda M, Yamane T, Mikami T, Nishida H, Nishio T, Akamatsu G, Ikari Y, Kimoto S, Aita K, Sasaki M, Shinkawa H, Yamamoto Y, Shukuri M, Mawatari A, Doi H, Watanabe Y, Onoe H.

Nucl Med Biol. 2016 Jul;43(7):438-44. doi: 10.1016/j.nucmedbio.2016.04.005. Epub 2016 Apr 28.

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review

Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z.

BMC Geriatr. 2016 May 16;16:104. doi: 10.1186/s12877-016-0281-7.

Quantitative MRI to understand Alzheimer's disease pathophysiology

Bozzali M, Serra L, Cercignani M.

Curr Opin Neurol. 2016 Aug;29(4):437-44. doi: 10.1097/WCO.0000000000000345.

Genome research in pre-dementia stages of Alzheimer's disease

Moreno-Grau S, Ruiz A.

Expert Rev Mol Med. 2016 May 30;18:e11. doi: 10.1017/erm.2016.12.

Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?

Kumar S, Reddy PH.

Biochim Biophys Acta. 2016 Sep;1862(9):1617-27. doi: 10.1016/j.bbadis.2016.06.001. Epub 2016 Jun 2.

[Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians]

Trombella S, Assal F, Zekry D, Gold G, Giannakopoulos P, Garibotto V, Démonet JF, Frisoni GB.

Rev Med Suisse. 2016 Apr 20;12(515):795-8.

Alterations in Glucose Metabolism in Alzheimer's Disease

Calsolaro V, Edison P.

Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):31-39. doi: 10.2174/1872214810666160615102809.

Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife

Racine AM, Koscik RL, Berman SE, Nicholas CR, Clark LR, Okonkwo OC, Rowley HA, Asthana S, Bendlin BB, Blennow K, Zetterberg H, Gleason CE, Carlsson CM, Johnson SC.

Brain. 2016 Aug;139(Pt 8):2261-74. doi: 10.1093/brain/aww142. Epub 2016 Jun 20.

A new biomarker classification system for AD, independent of cognition: Agnosticism is a start

Murray AD.

Neurology. 2016 Aug 2;87(5):456-7. doi: 10.1212/WNL.0000000000002931. Epub 2016 Jul 1.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.

Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias